ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States: Analysis of a Dataset From a Case-control Study
Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States (US)
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Maternal pertussis immunization and the blunting of routine vaccine effectiveness: a meta-analysis and modeling study.Nature communications · 2024Pooled it
- The association between vaccine hesitancy and pertussis: a systematic review and meta-analysis.Italian journal of pediatrics · 2023Pooled it
- Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review.BMC infectious diseases · 2020Pooled it
- Trial
- A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants.BMC medicine · 2021Trial
- Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.JAMA pediatrics · 2018Trial
- Waning immunity and the future of booster vaccination strategies in global vaccine programs post COVID-19.Human vaccines & immunotherapeutics · 2026Review
- Global, regional, and national burden of pertussis in children aged 0-14 years from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021.Infectious diseases & immunity · 2026Article
- A retrospective, single-center analysis of clinical features and mortality risk factors in pediatric pertussis patients with severe pneumonia and encephalopathy complications in Southwest China.Italian journal of pediatrics · 2026Article
- Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review.Infectious diseases and therapy · 2026Review
- Vaccination Status in Pregnancy: A Cross-Sectional Study of Two Greek Maternity Hospitals.Journal of pregnancy · 2026Article
- Evaluation of immune responses to Tdap booster during pregnancy in women who received whole cell or acellular pertussis vaccines during childhood.Emerging microbes & infections · 2025Article
- Inclusion of Women, Children, the Elderly, and Individuals With Underlying Medical Conditions: Prioritizing Vulnerable Populations in Clinical Research.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Article
- Pertussis resurgence: epidemiological trends, pathogenic mechanisms, and preventive strategies.Frontiers in immunology · 2025Review
- Impact of the US Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccination Program on Preventing Pertussis in Infants 2 to <6 Months of Age: A Case-Control Evaluation.Open forum infectious diseases · 2024Article
- Pertussis vaccines, epidemiology and evolution.Nature reviews. Microbiology · 2024Review
- Review
- Safety and immunogenicity of a single dose of Tdap compared to Td in pregnant women in Mali and 3 its effect on infant immune responses: a single-centre, randomised, double-blind, active-controlled phase 2 study.EClinicalMedicine · 2024Article
- Maternal hybrid immunity and risk of infant COVID-19 hospitalizations: national case-control study in Israel.Nature communications · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundInfants aged <1 year are at highest risk for pertussis-related morbidity and mortality. In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was recommended for women during each pregnancy to protect infants in the first months of life; data on effectiveness of this strategy are currently limited.
methodsWe conducted a case-control evaluation among pertussis cases <2 months old with cough onset between 1 January 2011 and 31 December 2014 from 6 US Emerging Infection Program Network states. Controls were hospital-matched and selected by birth certificate. Mothers were interviewed to collect information on demographics, household characteristics, and healthcare providers. Provider-verified immunization history was obtained on mothers and infants. Mothers were considered vaccinated during pregnancy if Tdap was received ≥14 days before delivery; trimester was calculated using Tdap date, infant's date of birth, and gestational age. Odds ratios were calculated using multivariable conditional logistic regression; vaccine effectiveness (VE) was estimated as (1 - odds ratio) × 100%.
resultsA total of 240 cases and 535 controls were included; 17 (7.1%) case mothers and 90 (16.8%) control mothers received Tdap during the third trimester of pregnancy. The multivariable VE estimate for Tdap administered during the third trimester of pregnancy was 77.7% (95% confidence interval [CI], 48.3%-90.4%); VE increased to 90.5% (95% CI, 65.2%-97.4%) against hospitalized cases.
conclusionsVaccination during pregnancy is an effective way to protect infants during the early months of life. With a continuing resurgence in pertussis, efforts should focus on maximizing Tdap uptake among pregnant women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.